Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study
Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to provide data regarding clinical and immunologic
activity of oral doses of pravastatin 80mg administered daily for 6 consecutive weeks, for
the treatment of active Crohn's disease as shown by the Harvey-Bradshaw Index (HBI) and/or
elevated C-reactive protein (CRP).
We hypothesize pravastatin will significantly reduce symptoms of Crohn's disease, as shown by
a decrease in HBI, by the end of the study period. Secondary outcomes of this study include
the effect of pravastatin on C-reactive protein, ESR, proinflammatory cytokines, and fecal
lactoferrin.